新型uPAR靶向光学显像剂FG001辅助恶性胶质瘤手术的首例人体研究
本研究在35例胶质母细胞瘤手术患者中开展首例人体I期剂量递增与时间优化研究,评估uPAR靶向近红外显像剂FG001的安全性与疗效。术前36 mg、12至17小时给药获得最佳对比,平均肿瘤背景比3.6,检测肿瘤组织敏感性79%、特异性100%,相关不良事件均为轻度。
要点
- FG001术前36 mg、12至17小时给药可获得最佳肿瘤对比。
- FG001检测肿瘤组织敏感性79%、特异性100%。
- 研究中相关不良事件少且均为轻度。
核心结论
- FG001在纳入研究的患者中安全且耐受良好。
- 基于术中视频与肿瘤背景比,选择36 mg为最佳剂量。
- 术前平均16小时给予36 mg显示最佳对比与肿瘤边界可视化。
研究设计与样本
- 首例人体I期剂量递增与时间优化研究,纳入35例接受胶质母细胞瘤手术的患者。
- 以近红外图像测量的肿瘤背景比作为图像对比的客观指标。
- 术中在荧光与非荧光区域取活检,以病理为参考对照。
主要发现
- 术前36 mg、12至17小时给药获得肿瘤与正常脑组织最佳图像对比,平均肿瘤背景比3.6。
- FG001检测肿瘤组织的敏感性为79%,特异性为100%。
- 研究期间安全监测仅发现少数相关不良事件,均为轻度。
关键数值与推荐
- FG001给药剂量为36 mg,于术前12至17小时给予时获得最佳图像对比。
- 平均肿瘤背景比为3.6。
- 检测肿瘤组织的敏感性为79%,特异性为100%。
临床怎么用
- 胶质母细胞瘤手术中可考虑术前36 mg、约16小时给予FG001以辅助肿瘤边界可视化。
- 术中可结合近红外成像的荧光信号指导活检与切除范围判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Glioblastoma is an aggressive form of brain cancer for which surgery is the keystone in treatment before oncological treatment. Improving surgical resection without jeopardizing the outcome is eminent, and a fluorescent drug to aid surgical outcome is warranted. To evaluate the safety and the efficacy of a novel urokinase-type Plasminogen Activator Receptor-targeting near-infrared optical imaging agent, ICG-Glu-Glu-AE105 (FG001), in patients with malignant glioma (glioblastoma). METHODS: First-in-human phase I dose escalation and time elaboration study in 35 patients undergoing surgery for glioblastoma. The tumor-to-background ratio (TBR) was measured on near-infrared images as an objective measure of image contrast. Biopsies were taken during surgery from areas with and without fluorescence (FG001) and compared with pathology as reference. Efficacy was evaluated as sensitivity and specificity of FG001 to detect tumor tissue. The study was conducted with close safety monitoring. RESULTS: Administration of FG001 at a dose of 36 mg, 12 to 17 hours before surgery, resulted in optimal image contrast between tumor and normal brain tissue, with a mean TBR of 3.6. A high sensitivity (79%) and specificity (100%) for the detection of tumor tissue was found. Safety monitoring during the study identified only a few related adverse events, all of which were of mild grade. CONCLUSION: FG001 was found to be safe and well tolerated in the patients included in the study. The optimal dose of FG001 was selected on the basis of videos taken during the surgery and the measured TBR values. A dose of 36 mg administered 16 hours (mean) before the surgery showed the best contrast (TBR values) and optimal visualization of the tumor delineation. Histology demonstrated good sensitivity of FG001.
引用
- Skjøth-Rasmussen J, Azam A, Juhl K, et al. Novel Urokinase-Type Plasminogen Activator Receptor-Targeting Optical Imaging Agent ICG-Glu-Glu-AE105 for Visualization of Malignant Glioma During Surgery: First-in-Human Study in 35 Patients with Brain Cancer. Neurosurgery. 2025. PMID: 40459950. doi:10.1227/neu.0000000000003542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。